<DOC>
	<DOCNO>NCT01084551</DOCNO>
	<brief_summary>The objective study evaluate clinical efficacy safety SPM962 patient restless legs syndrome ( RLS ) once-daily repeat dose 4.5mg 6.75mg 13-week dose-titration maintenance period . This multi-center , randomize , placebo-controlled , double-blind , 3-armed parallel group comparison study . Efficacy determine investigate superiority SPM962 placebo term primary efficacy variable , change International Restless Legs Syndrome Rating Scale ( IRLS ) total score baseline end dose-maintenance period .</brief_summary>
	<brief_title>Study SPM 962 Patients With Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<criteria>Patients whose condition diagnose RLS meeting 4 International Restless legs Syndrome Study Group/ National Institute Health ( IRLSSG/NIH ) criterion Patients meet follow criterion relate RLS treatment : Patients never receive treatment RLS Patients receive treatment RLS past respond Ldopa dopamine agonist ( Response RLS medicine irrelevant . ) Patients IRLS total score &gt; =15 baseline Patients experience symptom even night least two day week within 14 day prior commencement study treatment Patients partner practice contraception end followup observation period 1 week end treatment Patients previously participate clinical trial SPM962 take investigational product ( IP ) Patients secondary RLS induce renal impairment ( uremia ) , iron deficiency anemia , drug , pregnancy , etc . Patients currently suffer , risk developing , history sleep disorder sleep apnea syndrome , narcolepsy , sleep attacks/sudden onset sleep Patients concomitant disease symptom may affect symptom RLS , polyneuropathy ( include diabetic neuropathy ) , akathisia , claudication , varicoses , muscle fasciculation , painful leg move toe syndrome , radiculopathy folate deficiency Patients CNS diseases Parkinson 's disease , dementia , progressive supranuclear paresis , multisystem atrophy , Huntington 's Chorea , amyotrophic lateral sclerosis , Alzheimer 's disease Patients psychiatric condition confusion , hallucination , delusion , excitation , patient abnormal behavior delirium , obsessive compulsive disorder , impulse control disorder time screen test baseline examination Patients whose SBP decline least 30 mmHg supine stand position base orthostatic hypotension assessment , patient develop orthostatic hypotension baseline Patients history epilepsy , convulsion , etc Patients complication history serious cardiac disease arrhythmia ( eg , congestive heart failure class 3 4 NYHA classification , second third degree atrioventricular block , complete leave bundle branch block , sick sinus syndrome , ventricular fibrillation , myocardial infarction within 12 month prior screen test , complication angina pectoris ) Patients arrhythmia take Class 1a antiarrhythmic drug ( eg. , quinidine , procainamide ) Class 3 antiarrhythmic drug ( eg. , amiodarone , sotalol ) Patients serious ECG abnormality screen test baseline examination Patients show QTc interval exceed 450 ms ECGs screen test Patients average QTc interval two ECGs baseline assessment exceed 470 m ( female ) 450 m ( male ) Patients congenital long QT syndrome Patients whose serum potassium level &lt; 3.5mEq/L screen test Patients whose total bilirubin &gt; = 3.0mg/dL , whose AST ( GOT ) ALT ( GPT ) equal 2.5 time reference range clinical site ( &gt; = 100IU/L ) screen test Patients whose BUN level &gt; = 30mg/dL , whose serum creatinine level &gt; = 2.0mg/dL screen test Patients history allergy topical agent transdermal patch Patients pregnant nursing wish become pregnant study period Patients habitually drink alcohol smoke excessively Patients engage even shift work shift work , whose work circumstance make difficult maintain regular period sleep Patients engage hazardous work drive vehicle , operate machinery , work high location . Patients autoimmune disease , chronic active hepatitis , immune deficiency disorder Patients complication history malignant neoplastic disease , receive treatment disease within 12 month prior screen test Patients unable properly record information patient diary Patients receive IPs within 12 week prior commencement study treatment Patients judge investigator subinvestigator inappropriate inclusion study reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>